Staff editor

Seres Therapeutics takes key step toward SER-155 approval with positive FDA feedback on bloodstream infection prevention

Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…

The vaginal microbiome

Understanding the vaginal microbiome is essential not only for treating gynecological conditions but also for preventing them and promoting overall well-being.

SER-155’s early success in stem cell transplants: reducing infections and improving outcomes

Chris Ford, Senior Vice President, Translational Biology at Seres Therapeutics, discusses the development of SER-155, a cultivated bacterial consortium designed to address the unmet medical need of preventing bloodstream infections…

The gut microbiome

A comprehensive look at the gut microbiome’s structure, functions, and strategies for sustaining its health.

Understanding the physiology of hunger: an exclusive interview with Alessio Fasano

The discussion with Professor Alessio Fasano highlights the complex interplay between homeostatic, hedonic, and microbiota-driven mechanisms in regulating hunger.

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation (FMT) showing promise beyond C. difficile infection in conditions like IBD, IBS, and metabolic disorders.

Improving microbiome data reproducibility: key takeaways from Celine Druart (PRI) at the Microbiome Movement event

Celine Druart, from the Pharmabiotic Research Institute, highlighted critical challenges in the microbiome field, particularly around the standardization of clinical protocols and analytical methods. 

From supplements to drug development: how Biogaia navigates both worlds

Nigel Titford, CEO at Biogaia Pharma, discusses the strategic considerations and challenges involved in working across both the dietary supplement and pharmaceutical sectors. 

Flow VIT® Test Kits: The Next Step in Specific Probiotic Enumeration

In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top